IREB2 and prostate cancer: Our finding that IRP2 knockdown in prostate cancer cells recapitulates the effects of iron chelators on cell cycle inhibition [38, 39] (Figure 5) and induction of apoptosis [40–43] (Figure 6) suggests that targeting IRP2 may represent an alternative approach to restricting tumor growth by targeting iron.